Valtecne S.p.A.’s Strategic Shift to MedTech Drives Buy Rating

Analyst Gianluca Mozzali of Corporate Family Office SIM maintained a Buy rating on Valtecne S.p.A. (VLT – Research Report), with a price target of €8.50.

Gianluca Mozzali has given his Buy rating due to a combination of factors that highlight Valtecne S.p.A.’s strategic transition towards becoming a MedTech-focused company. The company has shown robust growth in its Medical Devices division, which has outpaced the market with a 7.9% organic increase, despite the overall sales decline due to the underperformance of its Industrial division.
Valtecne’s management is actively phasing out less profitable segments in the Industrial division, focusing instead on the high-growth potential of the Medical Devices sector. The integration of Utilità is expected to enhance cross-selling opportunities and further bolster the company’s core business. This strategic focus on MedTech, combined with the promising outlook for the Medical Devices market, supports the Buy rating.

VLT’s price has also changed moderately for the past six months – from EUR5.800 to EUR6.500, which is a 12.07% increase.